WORLD’s LARGEST CATALOG OF PREMADE Synthetic mRNA PRODUCTS
VISIT THE WORLD’S LARGEST CATALOG OF PREMADE SYNTHETIC mRNA
PRODUCTS: https://www.pharna.com/synthetic-mrna-products/
CONTACT US: customerservice@pharna.com FOR CUSTOM mRNA ORDERS AND GENERAL INQUIRIES.
PhaRNA, LLC: Is a comprehensive RNA biotechnology Company based in Houston, Texas. The company was founded in 2016 (long before the COVID19 pandemic) to meet the growing academic and industrial needs for vitro transcribed (IVT) messenger RNA (mRNA) reagents. Founded by scientists and entrepreneurs, PhaRNA possesses substantial expertise in the design, synthesis, and application of synthetic mRNA analogs for research, clinical, cosmetic, and veterinary use.
MISSION: The Company brings together extensive expertise of its founders to formulate lines of synthetic mRNA analogs that are engineered to maintain stability and eliminate cell and tissue toxicity. Understanding the limitations of current nucleic acid-based reagents, PhaRNA aims to provide non-integrating, high quality research- and clinical grade- mRNA analogs encoding any mammalian gene of interest or noncoding long RNAs. Our proprietary technology guarantees the production of RNA species that can be translated effectively and with great stability. Additionally, we provide RNA therapeutics services related to pre-IND and IND-enabling efficacy and toxicity studies.
Type of
mRNA
Catalog
Number
BioCapTM GFP mRNA
BioCapTM GFP-NLS mRNA
BioCapTM mCherry mRNA
BioCapTM fLuc mRNA
BioCapTM mCherry - NLS
BioCapTM rLuc mRNA
BioCapTM gLuc mRNA
100**
1500101
1500201
1500301
1500801
1500401
1500501
1500601
100
100
100
100
100
100
$320
$320
$275
$575
$275
$575
$275
Amount
(μg)
Price
The highest quality
and most affordable
synthetic mRNA* encoding
reporter proteins
on the market today.
*Cap1 Capped & 100% N1-Me-pU; **Minimum Available
mRNA categories:
PhaRNA, LLC offer several premade synthetic mRNAs encoding for some of the most common reporter proteins including mRNA of the Jellyfish GFP (green fluorescent protein), Discosoma mCherry (red fluorescent protein), firefly Luciferase (fLuc), renilla Luciferase (rLuc), gaussia Luciferase (gLuc) and beta-galactosidase (beta-Gal). In addition to these synthetic mRNAs encoding reporter proteins localized in the cellular cytosol, PhaRNA offers unique mRNAs encoding GFP-NLS and mCherry-NLS localized after translation in the nucleus. Such reporter proteins, which, after translation of the synthetic mRNA encoding them, are transferred into the nucleus, serve as the best control for those researchers who study structural, enzymatic and regulatory proteins functioning in the cell nucleus. Each synthetic mRNA encoding for reporter proteins localized in cellular cytosol or in nucleus can be readily assayed after translation and therefore used as control markers for mRNA packaging and delivery optimization in vitro and in vivo. These mRNAs are synthesized on error free sequence verified plasmid DNA based (non-PCR product) template with built-in constant poly-157A tail and enzymatically Cap1 caped, providing close to 100% capping efficiency and therefore superior mRNA stability and translatability.
GFP-NLS
mCherry
fLuc
rLuc
gLuc
b-Gal (CLB1)
Programmed cell death (apoptosis) is a physiological process that occurs in every nucleated cell. Apoptotic changes are characterized by cell membrane blebbing, nuclear fragmentation and chromatin condensation. Since apoptosis is a highly regulated process, a number of cell signaling pathways including caspases and proteases are involved in its initiation and execution. There has been growing interest in apoptosis research in part due to the essential role of this phenomenon in a number of disorders including developmental abnormalities, depletion of immune cells during viral infection, and carcinogenesis. Targeted genetic mutations, gene knockout and overexpression studies have significantly contributed to our understanding of the pathways involved in apoptotic processes. The overexpression studies, in particular, have used plasmid DNA and viral vectors to define the role of specific caspases. Emerging research indicates that mRNA mimetics have superior translational efficiency than plasmid DNA and thus provides a viable alternative to re-express knocked-out or disrupted proteins that are involved in apoptotic processes including tumor necrosis factor (TNF) or its receptors, p53, caspases 3, 8, 9, apoptotic protease activating factor 1 (APAF1), Fas-associated protein with death domatin (FADD), Bcl-2 homologous antagonist killer (BAK), Bcl-2 associated X protein (BAX) and yes-associated protein 1 (YAP1).
BAX
BAK1
YAP1 (Isoform YAP1-2alpha)
YAP1 (Isoform YAP1-2gamma)
Type I Cytokine Receptors include interleukin receptors, colony stimulating factor receptors, and hormone receptors whereas Type II Cytokine Receptors include inter feron receptors and cytokine receptors that bind to interleukin-10 family. Chemokine Receptors include receptors for C-C chemokine Type 1 (CCR1) and C-X-C Chemokine Type 4 (CXCR4). TGF beta Receptors include receptors for TGF beta 1 and TGF beta 2. The Immunoglobulin Superfamily include interleukin-1 receptor, interleukin-18 receptor, and c-Kit receptor. Finally, the Tumor Necrosis Factor Receptor Family include immune checkpoint molecules such as CD27, tumor markers such as CD30, and co-stimulatory molecules such as CD40. Due to their importance in cytokine-mediated immune response, cytokine receptors are actively pursued in biomedical research. Research has proven that mRNA mimetics have superior translational efficiency than recombinant DNA. In this regard, cytokine receptors may be expressed more efficiently using mRNA mimetics encoding these receptors.
Interleukins Receptors
Tumor Necrosis Factor (TNF) Receptors
Transforming Growth Factor (TGF) Receptors
Interferons Receptors
Cytokines are a family of cell signaling proteins that include Chemokines, Interleukins, Tumor Necrosis Factors (TNFs), Transforming Growth Factors (TGFs), Inter ferons, and Colony Stimulating Factors (CSFs). Cytokines are produced by immune and non-immune cells to modulate the immune system including response to microbial infection, inflammation, carcinogenesis, as well as control the maturation, growth and responsiveness of defined cell types. Some of the cell types that secrete cytokines include lymphocytes, macrophages, fibroblasts, endothelial cells and stromal cells. Cytokines have been demonstrated to be involved in a number of diseases including cancer, cardiovascular, neurological and immune-mediated disorders. Drug discovery and development efforts have produced several recombinant DNA and recombinant protein-based cytokines as therapy to treat a number of disorders including anemia (using recombinant erythropoietin), neutropenia (G-CSF), thrombocytopenia (IL-11), cancer (IL-2), bone disorders (interferon gamma), hepatitis and multiple sclerosis (interferon alpha/beta). Research has proven that mRNA mimetics have superior translational efficiency than recombinant DNA and, unlike recombinant proteins, can be endogenously modified in vivo.
Cytokines
Tumor Necrosis Factor (TNF)
Transforming Growth Factor (TGF)
Interferons
Colony-Stimulating Factors (CSFs)
Growth factors including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF) and epidermal growth factor (EGF) are important molecules that control cellular growth, proliferation, and differentiation. For example, VEGF, FGF and PDGF support the formation and growth of blood vessels while EGF enhances bone regeneration. Additional research shows the essential role of growth factors in wound healing and carcinogenesis. Similar to cytokines, growth factors have been used in medicine to treat a number of disorders including anemia, leukemias and cardiovascular disease to stimulate angiogenesis. The growth factors in medical use so far have been produced using recombinant DNA or recombinant protein approaches. Research has proven that mRNA mimetics have superior translational efficiency than recombinant DNA and, unlike recombinant proteins, can be endogenously modified in vivo.
Vascular Endothelial Growth factors (VEGFs)
Platelet-derived Growth factors (PDGFs)
Fibroblast Growth Factors (FGFs)
Insulin-like Growth Factors (IGFs)
Epidermal Growth Factors (EGFs)
Advancing age is associated with increased risk of cardiovascular diseases such as atherosclerosis, hypertension, diabetes and heart attack. Some of the derangements that manifest with advancing age are DNA damage, telomere erosion, genome instability, mutagenesis and cellular senescence. These derangements are in part mediated by dysfunction of genes that are involved in genome integrity and cellular plasticity. Some of these key genes include the telomerase enzyme complex including telomerase reverse transcriptase (TERT), telomerase RNA (TERC), dyskerin, and subunits of the shelterin complex, as well as sirtuin 1 (SIRT1). Proof-of-concept genetic studies have reported that TERT reactivation increases longevity and favorably modulates cardiovascular diseases. More recently, it has been demonstrated that introduction of exogenously expressed TERT in the form of modified messenger RNA (mmRNA) increases TERT enzymatic activity and transiently extends telomere length in primary human cells. This technology may be able to delay cellular and tissue senescence, and increase the proliferative capacity of cells without immortal transformation. PhaRNA, LLC has an inventory of mRNA mimetics encoding several members of the aging-associated genes. In the event that we don't have in stock, we can custom make mRNA transcripts encoding your gene of interest.
Human TERT-CI (D712A)
Human TERT 5'-3xFLAG
Human TERT 3'-3xFLAG
Human TERT 5'-3xFLAG 3'-NLS
Human TERT CI (D712A) 5'-3xFLAG
Human TERT CI (D712A) 3'-3xFLAG
Human TERT CI (D712A) 5'-3xFLAG 3'-NLS
Mouse Tert
Mouse Terc
Growth factor receptors bind to growth factors to mediate cell biological processes including cell proliferation, differentiation and survival. The most common growth factors that utilize these receptors include vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and epidermal growth factors (EGF). These growth factors are their receptors have extensively been studied in cardiovascular and cancer research. In cardiovascular research, growth factors such as VEGF have been used as ligands to stimulate angiogenesis whereas in cancer research inhibition of dysregulated growth factor receptors is the premise for several clinically used drugs including inhibitors of VEGF receptor (VEGFR), EGR receptor 1 (HER1), and EGF receptor 2 (HER2). Although small molecules have been successfully developed to target growth factor receptors, RNA in the form of small interference RNA and antisense RNA has been used to block growth factor receptors. By extension, mRNA mimetics to express dominant-negative mutants can be used to selectively target tumorigenic receptors and signaling pathways.
Vasc. Endothelial Growth Factor (VEGF) Receptors
Platelet-derived Growth Factor (PDGF) Receptors
Fibroblast Growth Factor (FGFs) Receptors
Insulin-like Growth Factor (IGFs) Receptors
Epidermal Growth Factor (EGFs) Receptors
Several transcription factors have been used for nuclear reprogramming, differentiation of embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) into somatic cells, and transdifferentiation of one somatic cell type into another. For nuclear reprogramming, a set of “Yamanaka - Thomson Factors” have been used to convert fibroblasts into iPSCs. Subsequently, several studies have differentiated iPSCs into endothelial cells, cardiomyocytes, hematopoietic cells, beta cells, hepatocytes, osteoclasts and neurons. In addition, somatic cells such as fibroblasts have been directly converted into endothelial cells, cardiomyocytes, hematopoietic cells, as well as the other somatic cell types described above. Almost all of the studies that provided proof-of-concept data for nuclear reprogramming, differentiation and transdifferentiation used recombinant DNA or viruses that have the potential to integrate into the genome and induce undesired effect. By contrast, mRNA mimetics is a non-integrating approach that can efficiently convert cell fate including through nuclear reprogramming.
Endothelial Differentiation Factors
Cardiomyocyte and Myocyte Diffrntiation Factors
Blood and Hematopoietic Differentiation Factors
Beta Cell Differentiation Factors
Hepatocyte Differentiation Factors
Neuronal Differentiation Factors
Osteoclast Differentiation Factors
This category of mRNA mimetics contains growing list of genes that are involved in various cellular and molecular processes. Currently, this list contains transcription factors, stromal cell-derived factors, myocyte-specific enhancers, and genes involved in tissue remodeling. PhaRNA, LLC will continue to grow this ‘miscellaneous’ category by adding a number of genes that are commonly used by biomedical researchers into its archive. In the meantime, if you are interested in having your gene of interest custom made by our scientists, please contact us at customerservice@pharna.com and it is our promise to timely fulfill your needs.
SERPINA1
SERPINA1 Z Type Mutant
ELANE
CXCL12 Isoform Alpha
CXCL12 Isoform Gamma
OLA1
Mef2c
Tbx5
Gata4
Hand2
Pou3f2
pou3f2 (Zebrafish)
Distributors:
Testimonials
“mGFP mRNA we bought for Pharna was good. We got very good transfection and GFP fluorescence was bright.”
- Bindu Thapa (University of Alberta)
“I’m excited to inform you that the manuscript we had submitted last year has been accepted for publication in Stem Cells. It includes some data generated using the TERT and GFP mmRNA from your company. We look forward to being able to collaborate with you again in the future!”
- Nirmala Hariharan (University of California – Davis)